Freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-23. Anything still debated is marked as such rather than presented as settled.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Per a 1970 paper reporting the parent cation's isolation, "Simple mixing of 3-chlorocyclopropene with antimony pentachloride, aluminum trichloride, or silver fluoroborate...[leads] to the salts of cyclopropenyl cation." The hexachloroantimonate (SbCl−6) salt is indefinitely stable at −20 °C. Trichlorocyclopropenium salts are generated by chloride abstraction from tetrachlorocyclopropene:
Stalin's Gulag was, in many ways, less a concentration camp than a forced labor camp and less a prison system than a system of slavery. The image of the slave appears often in Gulag memoir literature. As Varlam Shalamov wrote: "Hungry and exhausted, we leaned into a horse collar, raising blood blisters on our chests and pulling a stone-filled cart up the slanted mine floor. The collar was the same device used long ago by the ancient Egyptians." Thoughtful and rigorous historical comparisons of Soviet forced labor and other forms of slave labor would be worthy of scholarly attention, in my view. For as in the case of global slavery, the Gulag found legitimacy in an elaborate narrative of difference that involved the presumption of dangerousness and guilt. This ideology of difference and the violence of human exploitation have left lasting legacies in contemporary Russia.
Sponsors Boy and Girl Scout troops, Red Cross, various parish functions, church retreats, visits the sick and assists the needy, sponsors masses; and supports students studying theology and Catholic educational activities. Merged into the First Catholic Slovak Ladies Association in 2004. Knights of Columbus Knights of Peter Claver - Founded in 1909 by members of Most Pure Heart of Mary Catholic Church in Mobile, Alabama, as a Black Catholic fraternal order, as Blacks were barred from the Knights of Columbus due to their race. Among the founders were The Rev. John H. Dorsey (the second Black Catholic priest ordained in the US), many White priests, and three Black parishioners. Knights of St. John - Founded in 1879. Membership is open to "practical Catholic gentlemen" ages 16–55. Social membership available was also available, even to those over 55. In 1978 there were 7,144 members. The international structure is called the "Supreme Commandery", regional structures "Grand Commanderies", and local units are called "Commanderies". There were 172 Commanderies in 1978 including 27 in "West Africa", 5 in Togo, and 8 in Trinidad and Tobago. The order has a secret ritual but dropped password in April 1977 because it was time-consuming and had "no appreciable organizational value". The group appears in uniforms for Catholic ceremonies such as first communions Masses, and confirmations. The order has a sports program that sponsors golf and bowling. There is also a death benefit.
This certificate serves as a benchmark for high standards in the specialty across Europe and is increasingly recognized by various national regulatory authorities. In the United States, physicians who practice clinical genetics are accredited by the American Board of Medical Genetics and Genomics (ABMGG). In order to become a board-certified practitioner of Clinical Genetics, a physician must complete a minimum of 24 months of training in a program accredited by the ABMGG. Individuals seeking acceptance into clinical genetics training programs must hold an M.D. or D.O. degree (or their equivalent) and have completed a minimum of 12 months of training in an ACGME-accredited residency program in internal medicine, pediatrics, obstetrics and gynecology, or other medical specialty. In Australia and New Zealand, clinical genetics is a three-year advanced training program for those who already have their primary medical qualification (MBBS or MD) and have successfully completed basic training in either paediatric medicine or adult medicine. Training is overseen by the Royal Australasian College of Physicians with the Australasian Association of Clinical Geneticists contributing to authorship of the curriculum via their parent organization, the Human Genetics Society of Australasia.
=== Before the search === The earliest mention of some matter with the properties of deuterium was a passing mention in Ernest Rutherford's 1919 Bakerian lecture. In this theory, the deuterium nucleus with mass two and charge one would contain two protons and one nuclear electron. Also in 1919, Otto Stern and Max Volmer reported on diffusion experiments with water which they claimed disproved the existence of isotopes of hydrogen; their conclusions were assumed to be correct throughout the 1920s.
Sources: en.wikipedia.org
=== United States === In the US, Good Manufacturing Practice (GMP) Regulations are based on the Code of Federal Regulations 21 CFR 210/211, and USP 1079. The US Drug Supply and Chain Security Act (DSCSA), was enacted by Congress on November 26, 2013 and outlines requirements to build electronic systems that identify and trace prescription drugs distributed in the US. By November 27th 2023, full electronic track & trace capability will be required for all partners in the supply chain.
Agricultural technology Food biotechnology Food packaging Food grading Molecular gastronomy Optical sorting Standard components (food processing) List of food and drink awards § Food technology awards Timeline of culinary technologies
== Overdose == There have been cases of death with dimethyltryptamine (DMT). In terms of extrapolated human lethal dose based on animal studies and human case reports, the lethal dose of ayahuasca relative to a typical recreational or entheogenic dose is estimated to be 50-fold.
Pasqualini syndrome Kallmann syndrome Hypothalamic suppression Hypopituitarism Eating disorder Female athlete triad Hyperprolactinemia Hypogonadism Gonadal suppression therapy GnRH antagonist GnRH agonist (inducing an initial stimulation (flare up) followed by permanent blockage of the GnRH pituitary receptor)
Contracting blood-borne pathogens such as HIV and hepatitis via the sharing of needles Contracting bacterial or fungal endocarditis and possibly venous sclerosis Abscesses Poisoning from contaminants added to "cut" or dilute heroin Decreased kidney function (nephropathy), although it is not currently known if this is because of adulterants or infectious diseases
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.